Cargando…

Pan-Bcl-2 Inhibitor Obatoclax Delays Cell Cycle Progression and Blocks Migration of Colorectal Cancer Cells

Despite the fact that new treatment regimes have improved overall survival of patients challenged by colorectal cancer (CRC), prognosis in the metastatic situation is still restricted. The Bcl-2 family of proteins has been identified as promising anti cancer drug target. Even though small molecules...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koehler, Bruno Christian, Scherr, Anna-Lena, Lorenz, Stephan, Elssner, Christin, Kautz, Nicole, Welte, Stefan, Jaeger, Dirk, Urbanik, Toni, Schulze-Bergkamen, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156353/ https://www.ncbi.nlm.nih.gov/pubmed/25192188 http://dx.doi.org/10.1371/journal.pone.0106571

Ejemplares similares

Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling
por: Koehler, Bruno Christian, et al.
Publicado: (2015)

Beyond Cell Death – Antiapoptotic Bcl-2 Proteins Regulate Migration and Invasion of Colorectal Cancer Cells In Vitro
por: Koehler, Bruno Christian, et al.
Publicado: (2013)

Nuclear Expression of the Deubiquitinase CYLD Is Associated with Improved Survival in Human Hepatocellular Carcinoma
por: Welte, Stefan, et al.
Publicado: (2014)

Bcl-x(L) is an oncogenic driver in colorectal cancer
por: Scherr, Anna-Lena, et al.
Publicado: (2016)

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2020)

Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
por: Kim, Peter S, et al.
Publicado: (2014)

Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells
por: Scherr, Anna-Lena, et al.
Publicado: (2020)

Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells
por: Or, Chi-Hung R., et al.
Publicado: (2016)

Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade
por: Li, Jingye, et al.
Publicado: (2021)

Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling
por: Or, Chi-Hung R., et al.
Publicado: (2020)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells
por: Yu, Le, et al.
Publicado: (2016)

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer
por: Chiappori, A A, et al.
Publicado: (2012)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis
por: Champa, Devora, et al.
Publicado: (2016)

Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016)

Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax
por: Lima, Keli, et al.
Publicado: (2022)

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells
por: Jiménez-Guerrero, Rocío, et al.
Publicado: (2018)

GX15–070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma
por: Cournoyer, Sonia, et al.
Publicado: (2019)

An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies
por: Goard, Carolyn A, et al.
Publicado: (2013)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
por: Andersen, Petter I., et al.
Publicado: (2019)

OBATOCLAX and ABT-737 Induce ER Stress Responses in Human Melanoma Cells that Limit Induction of Apoptosis
por: Wroblewski, David, et al.
Publicado: (2013)

Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro
por: Varghese, Finny S., et al.
Publicado: (2021)

Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer
por: Wei, Wei-Jun, et al.
Publicado: (2017)

Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity
por: Ehrenkaufer, Gretchen, et al.
Publicado: (2020)

Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK
por: McCoy, F, et al.
Publicado: (2010)

Obatoclax Regulates the Proliferation and Fusion of Osteoclast Precursors through the Inhibition of ERK Activation by RANKL
por: Oh, Ju Hee, et al.
Publicado: (2015)

Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma
por: Espona-Fiedler, Margarita, et al.
Publicado: (2022)

Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy
por: Castillo Bautista, Cristina Marisol, et al.
Publicado: (2023)

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells
por: Su, Jung-Chen, et al.
Publicado: (2014)

An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1
por: Zhang, Z, et al.
Publicado: (2013)

Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer
por: Scherr, Anna-Lena, et al.
Publicado: (2020)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
por: Eustace, Alex J, et al.
Publicado: (2018)

Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
por: Ramakrishnan, Vijay, et al.
Publicado: (2016)

Pan-Bcl-2 Inhibitor AT-101 Enhances Tumor Cell Killing by EGFR Targeted T Cells
por: Thakur, Archana, et al.
Publicado: (2012)

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction
por: Schulze-Bergkamen, Henning, et al.
Publicado: (2006)

Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
por: Richter, Anna, et al.
Publicado: (2021)

Liver cancers with stem/progenitor-cell features – a rare chemotherapy-sensitive malignancy
por: Köhler, Bruno Christian, et al.
Publicado: (2017)

GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
por: Heidari, N, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_bcdfanbnioouqkhoess8hono5b